Drug: Dritho-Scalp

Dritho-Scalp® is a pale yellow topical cream containing 0.5% anthralin USP in a base of white petrolatum, mineral oil, sodium lauryl sulfate, cetostearyl alcohol, ascorbic acid, salicylic acid, methylparaben and purified water. The chemical name of anthralin is l,8-dihydroxy-9- anthrone. The structural formula is:

Source: http://www.rxlist.com

Very few instances of contact allergic reactions to anthralin have been reported. However, transient primary irritation of uninvolved skin surrounding the treated lesions is more frequently seen and may occasionally be severe. Application of Dritho-Scalp must be restricted to the psoriatic lesions. If the initial treatment produces excessive soreness or if the lesions spread, reduce frequency of application and, in extreme cases, discontinue use and consult physician. Some temporary discoloration of hair and fingernails may arise during the period of treatment but should be minimized by careful application. Dritho-Scalp may stain skin, hair or fabrics. Staining of fabrics may be permanent, so contact should be avoided. Read the Dritho-Scalp (anthralin) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

Generally, it is recommended that Dritho-Scalp be applied once a day or as directed by a physician. Anthralin is known to be a potential skin irritant. The irritant potential of anthralin is directly related to each patient's individual tolerance. Therefore, where the response to anthralin treatment has not previously been established, always commence treatment using a short contact time of 5 to 10 minutes for at least one week using Dritho-Scalp. Contact time can be increased stepwise to twenty to thirty minutes, or as directed by a physician, before removing the cream by thoroughly washing or showering. Apply as directed by a physician. The optimal period of contact will vary according to the patient's response to treatment. To open the tube, unscrew the cap and invert to pierce the membrane. Comb the hair to remove scalar debris and, after suitably parting, apply Dritho-Scalp only to the lesions and rub in well, taking care to prevent the cream spreading onto the forehead. Keep Dritho-Scalp well away from the eyes. Avoid application of the cream to uninvolved scalp margins. Remove any unintended residue which may be deposited behind the ears. At the end of each period of contact, wash the hair and scalp to remove any surplus cream (which may have become red/brown in color). Always wash hands thoroughly after use. Store at controlled room temperature, 15-30C (59-86F).

Source: http://www.rxlist.com

No information provided. Last reviewed on RxList: 5/26/2011
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

An aid in the topical treatment of quiescent or chronic psoriasis of the scalp. Treatment should be continued until the skin is entirely clear, i.e., when there is nothing to feel with the fingers and the texture is normal.

Source: http://www.rxlist.com

In patients with acute psoriatic eruptions or a history of hypersensitivity to any of the ingredients. Last reviewed on RxList: 5/26/2011
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

No information provided.

Source: http://www.rxlist.com

50 g tube Manufacturer details: n/a Last reviewed on RxList: 5/26/2011
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

For external use only. Dritho-Scalp may stain the hair and should be applied sparingly and carefully to psoriatic lesions only. Contact with fabrics, plastics and other materials may cause staining and should be avoided. To prevent the possibility of discoloration, always rinse the bath/shower with hot water immediately after washing/showering and then use a suitable cleanser to remove any deposit on the surface of the bath or shower. Always wash hands thoroughly after use, 15-30° C (59-86° F). Long-term studies in animals have not been performed to evaluate the carcinogenic potential of the drug. Although anthralin has been found to have tumor-promoting properties on mouse skin, there have been no reports to suggest carcinogenic effects in humans after many years of clinical use. As long-term use of topical corticosteroids may destabilize psoriasis, and withdrawal may also give rise to a 'rebound' phenomenon, an interval of at least one week should be allowed between the discontinuance of such steroids and the commencement of Dritho-Scalp therapy. Petrolatum or a suitably bland emollient may usefully be applied during the intervening period. Pregnancy Pregnancy Category C. Animal reproduction studies have not been conducted with Dritho-Scalp. It is also not known whether Dritho-Scalp can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dritho-Scalp should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in milk and because of the potential for tumorigenicity shown for anthralin in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Last reviewed on RxList: 5/26/2011
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Health Services in

Drug Database Online

Welcome to Vaccine Health Center an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically Dritho-Scalp. Find what medications you are taking today.